Sandoz reaches $469 mln settlement with US states in generic drug antitrust case
( August 3, 2026, 14:39 GMT | Official Statement) -- MLex Summary: Sandoz reached a $469 million settlement with a coalition of 43 attorneys general to resolve claims that it conspired to artificially inflate generic drug prices and reduce competition, Connecticut Attorney General William Tong announced. “Sandoz rigged the generic drug market, forcing customers to pay higher prices for critical medication. The company then fraudulently shielded its assets to evade accountability. This settlement in principle ensures the company takes responsibility for its brazen actions and is a major step as we head to our first trial,” Tong said.Statement follows in full. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.